The DOI matches its Crossref record; 101 of the 105 references it cites were found in a registry or an index.
Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors
Abstract
Cholinesterase inhibitors are the 'first-line' agents in the treatment of Alzheimer's disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity. Tacrine was the first cholinesterase inhibitor approved by regulatory agencies, followed by donepezil, rivastigmine and recently galantamine. With the exception of low doses of tacrine, the cholinesterase inhibitors exhibit a linear relationship between dose and area under the plasma concentration-time curve. Cholinesterase inhibitors are rapidly absorbed through the gastrointestinal tract, with time to peak concentration usually less than 2 hours; donepezil has the longest absorption time of 3 to 5 hours. Donepezil and tacrine are highly protein bound, whereas protein binding of rivastigmine and galantamine is less than 40%. Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil and galantamine are metabolised by CYP3A4 and CYP2D6. Rivastigmine is metabolised by sulfate conjugation. Two cholinesterase enzymes are present in the body, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Tacrine and rivastigmine inhibit both enzymes, whereas donepezil and galantamine specifically inhibit AChE. Galantamine also modulates nicotine receptors, thereby enhancing acetylcholinergic activity at the synapse. These different pharmacological profiles provide distinctions between these agents. Cholinesterase inhibitors show a nonlinear relationship between dose and cholinesterase inhibition, where a plateau effect occurs. Cholinesterase inhibitors display a different profile as each agent achieves its plateau at different doses. In clinical trials, cholinesterase inhibitors demonstrate a dose-dependent effect on cognition and functional activities. Improvement in behavioural symptoms also occurs, but without a dose-response relationship. Gastrointestinal adverse events are dose-related. Clinical improvement occurs with between 40 and 70% inhibition of cholinesterase. A conceptual model for cholinesterase inhibitors has been proposed, linking enzyme inhibition, clinical efficacy and adverse effects. Currently, measurement of enzyme inhibition is used as the biomarker for cholinesterase inhibitors. New approaches to determining the efficacy of cholinesterase inhibitors in the brain could involve the use of various imaging techniques. The knowledge base for the pharmacokinetics and pharmacodynamics of cholinesterase inhibitors continues to expand. The increased information available to clinicians can optimise the use of these agents in the management of patients with Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“different cholinesterase inhibitors such as donepezil, rivastigmine, and tacrine are used to treat AD, and their side effects are becoming increasingly remarkable [103,104].”
From Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review (2020) · cites this paper as [104]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Research works printed but not linked: 12
- Cutler, 1990, Psychopharmacol Bull, 26, 231
- Schran, 1996, Pharm Res, 13, S
- Johansson, 1993, Acta Neurol Scand, 149, 22
- Welty, 1993, Pharm Res, 10, S344
- Ravic, 2001, Clin Pharmacol Ther, 69, P44
- Reyes, 2001, Clin Pharmacol Ther, 69, P44
- DeJong, 1989, Clin Ther, 11, 545
- Knapp, 1994, JAMA, 271, 985, 10.1001/jama.1994.03510370037029 · DOI
- Corey-Bloom, 1999, Int J Geriatr Psychopharmacol, 1, 55
- Anand, 2000, Int J Geriatr Psychopharmacol, 2, 68
- Farlow, 1992, JAMA, 268, 2523, 10.1001/jama.1992.03490180055026 · DOI
- Steele, 1999, J Clin Outcome Management, 6, 52
Cited by
Sorted by citations
Items 301–368 of 368
Temel, H. E., Çiftçi, G. A., & Yurttaş, L. (2023) · European Journal of Life Sciences · doi:10.55971/ejls.1328405 · Cited by 1
The molecular mechanisms of Abyssinone-I protect against Alzheimer’s disease: an in-silico study
Nguyen, H. D. (2024) · Discover Medicine · doi:10.1007/s44337-024-00009-7 · Cited by 1
Gadiko, C. (2013) · Scientia Pharmaceutica · doi:10.3797/scipharm.1302-13 · Cited by 1
Development of Different Polymer Matrix Systems for Galantamine Hydrobromide Sustained Release
Aleksiev, A., Kostova, B., & Rachev, D. (2015) · Cited by 1
Advances in Therapies and Scope for Personalized Medicine in Alzheimer’s Disease
Ravishankar, H. N., Dutta, A. K., Lewis, A. G., & Mohan, A. (2016) · Personalized Medicine · doi:10.2217/pme.15.49 · Cited by 1
Acetylcholinesterase inhibitors for autistic spectrum disorders
Cox, G., Williams, K. J., Woon, J. M., Haslam, R., & Ure, A. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013851 · Cited by 1
Böhm, S. (2020) · Springer eBooks · doi:10.1007/978-3-662-58304-3_35 · Cited by 1
Wojtera, M., & Sobów, T. (2014) · Aktualności Neurologiczne · doi:10.15557/an.2014.0025 · Cited by 1
A transdermal patch in Alzheimer disease
Cummings, J. L. (2007) · Neurology · doi:10.1212/01.wnl.0000281844.32766.24 · Cited by 1
Fasinu, P. S. (2010) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg) · Cited by 1
Jeremias, I. C. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2015.tde-06112015-143205 · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1
Khaleseh, F., Haghi‐Aminjan, H., & Samadi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00951-9 · Cited by 1
Consideraciones geri?tricas de las enfermedades neurodegenerativas. Demencia
Gregório, P. G., & Snchez, F. J. M. (2006) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(06)74370-3
Wezenberg, E. (2008) · Radboud Repository (Radboud University)
Gordon, R. K., Haigh, J. R., Garcia, G. E., Feaster, S. R., Doctor, B. P., Riel, M. A., Lefkowitz, L. J., Lenz, D. E., Aisen, P. S. S., & Smart, W. H. (2006) · Army Science Conference (ASC) · doi:10.1142/9789812772572_0052
Pharmacotherapy, clinical pharmacology and biomarker research in geriatric patients
Frankfort, S. V. (2007) · Utrecht University Repository (Utrecht University)
Pharmacological fMRI; a clinical exploration
Goekoop, R. (2006) · Data Archiving and Networked Services (DANS)
Investigação de associação entre a Butirilcolinesterase e a doença de Alzheimer
Bono, G. F. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Dose Adaptation of Drugs in Patients with Liver Disease
Fakultät, P.-N. (2004)
Hsiung, G. R., & Feldman, H. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-661-4_20
Alzheimer-Demenz und weitere neurodegenerative Erkrankungen
Behl, C. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_28
Application of TK/PD modeling in predicting dose-limiting toxicity
Yu, L., Silverman, L. R., Alden, C. L., Liu, G., Prakash, S. R., & Lee, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.019
Shua‐Haim, J. R., Smith, J. M., Lefèvre, G. Y., Picard, F., Sedek, G., Athalye, S. N., & Pommier, F. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.2152
Optical Detection of Interaction between Alzheimer's Disease Biomarkers and Carbon Nanotubes
Zaheer, A. (2014) · TSpace (University of Toronto)
Kohli, N. (2012) · Journal of International Crisis and Risk Communication Research
O'Regan, J. (2014) · TSpace (University of Toronto)
Patel, S., Barot, B. S., Parejiya, P. B., Shelat, P., Shukla, A., & Pvt, I. (2012)
Dunne, R. A., & Burns, A. S. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.016
Hui, J. (2019) · TSpace (University of Toronto)
Real Life Experiences Using the WRAIR Whole Blood and Pyridostigmine Assays
Haigh, J. R., Garcia, G. E., Moorad‐Doctor, D., Farah, M. S., Doctor, B. P., Feaster, S. R., Gordon, R. K., Lenz, D. E., Clark, C. R., & Riel, M. A. (2005) · Defense Technical Information Center (DTIC)
Heuser, I., & Anghelescu, I. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_32
Therapeutic Agents for Neurodegenerative Disorders
Merino, P. (2019) · doi:10.1002/9783527813421.ch10
Donepezil: a guide to its use in Alzheimerʼs disease
&NA; (2009) · Drugs & Therapy Perspectives · doi:10.2165/0042310-200925090-00002
Heuser, I., & Förstl, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_57
Rikkert, M. G. M. O., & Verhey, F. R. J. (2007) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6431-2_36
VanDenBerg, C. M., & Jann, M. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_13
Self-citationClaassen, J. A. H. R., Verhey, F. R. J., & Rikkert, M. G. M. O. (2013) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-9265-0_30
Böhm, S. (2012) · Springer-Lehrbuch · doi:10.1007/978-3-642-12354-2_35
Böhm, S. (2016) · Springer-Lehrbuch · doi:10.1007/978-3-662-46689-6_35
Yaowaluk, T., Senanarong, V., Limwongse, C., Boonprasert, R., Bunditvorapoom, D., Kaewsutthi, S., & Kijsanayotin, P. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03322-1
Donepezil to lecanemab-advancements in targeted therapy of Alzheimer’s disease so far
Khanam, F. M. (2023) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20232215
Yaowaluk, T., Kijsanayotin, P., Senanarong, V., & Limwongse, C. (2018) · doi:10.58837/chula.the.2018.438
Andrýs, R., Monnier, C., Miljaković, E. A., Mickova, V., Musílek, K., & Zemanová, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4580969
Koźmiński, P., & Gniazdowska, E. (2024) · Applied Sciences · doi:10.3390/app14072827
Ahmad, S. R., Zeyaullah, M., AlShahrani, A. M., Muzammil, K., Khan, M. S. A. A., Qavi, D., Husain, I., Altijani, A. A. G., Dawria, A., Mohieldin, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4656533/v1
Chaudhuri, К. R., Jenner, P. G., Leta, V., Jones, S., & Boura, I. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009222648.042
Modric, M., Gentile, R., Schröder, L. C., Moll, R., Alio, I., Streit, W. R., Jaeger, K., Gohlke, H., & Kovačić, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.23.644859
Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Cacabelos, P., & Naidoo, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00032-3
Majumder, S., Pal, S., Yadav, A., Mondal, A., & Bisai, A. (2025) · Tetrahedron · doi:10.1016/j.tet.2025.134884
Brazilian Hippeastrum (Amaryllidaceae): A review of the chemistry and biological activity
da Silva, T. R. L. P., da Silva, J. F. P., Gomes-Copeland, K. K. P., Gomes, J. V. D., Estrada-Semprun, O. E., Fonseca-Bazzo, Y. M., Magalhães, P. O., & Silveira, D. (2025) · Studies in natural products chemistry · doi:10.1016/b978-0-443-45775-3.00005-3
Therapeutic approaches to age related cognitive decline and neurodegenerative diseases
Nandi, N. K., Singhal, A., & Tripathi, P. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36295-8.00009-2
Spector, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00021-3
Havreng‐Théry, C., Oquendo, B., Zolnowski‐Kolp, V., Krolak‐Salmon, P., Bertin‐Hugault, F., Lafuente‐Lafuente, C., & Belmin, J. (2024) · Figshare · doi:10.6084/m9.figshare.26727082
Carreiro, E. P., Múria, P., Velez, D. H. G., Carrott, M. R., Burke, A. J., & Costa, A. R. (2026) · Polymers · doi:10.3390/polym18020234
Paez, K., Kopachik, C., Yılmaz, A., Vishweswaraiah, S., Ashrafi, N., Saiyed, N., Monacelli, N., Kerševičiūtė, I., Gordevicius, J., Ruff, S., et al. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251387281
Rocuronium resistance associated with rivastigmine transdermal therapy
Kumar, A., Chauhan, A., & Sharma, K. (2026) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_94_26
da Silva, T. M., Meulman, J., Vianna, D. R. B., Fortuny, M., Scasso, A., Bellório, K. B., Caçula, A. C. C. S. M., Teixeira, L. D. S., Costa, F., & Vespasiano, C. F. P. (2026) · Research Square · doi:10.21203/rs.3.rs-9692373/v1
Jung, I., Kim, J., & Park, M. H. (2026) · Journal of Eye Movement Research · doi:10.3390/jemr19050094
BindingDB (2017) · UC San Diego · doi:10.7270/q2xw4mpw
BindingDB Entry 6743: Salicylanilide diethyl phosphates as cholinesterases inhibitors.
BindingDB (2015) · UC San Diego · doi:10.7270/q26d5rq1
Gordon, R. K., Haigh, J. R., Garcia, G. E., Moorad‐Doctor, D., Farah, M. S., Brueckner, R. P., Feaster, S. R., Doctor, B. P., Lenz, D. E., & Clark, C. R. (2004) · Defense Technical Information Center (DTIC)
Metadata
- Authors
- Jann, M. W., Shirley, K. L., & Small, G. W.
- Affiliations
- Mercer University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Jann, Michael W.
- Venue
- Clinical Pharmacokinetics
- Published
- 2002
- Volume
- 41
- Issue
- 10
- Pages
- 719-739
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2016149437
- Cited by
- 365
- References
- 105
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 13 · 2023: 11 · 2022: 10 · 2021: 12 · 2020: 19 · 2019: 23 · 2018: 11 · 2017: 7 · 2016: 17 · 2015: 17 · 2014: 23 · 2013: 11 · 2012: 16
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- cholinesterase inhibitors, Alzheimer's disease, pharmacokinetics, pharmacodynamics, tacrine, donepezil, rivastigmine, galantamine, acetylcholinesterase inhibition, butyrylcholinesterase, dose-response relationship, plateau effect, drug metabolism, cytochrome P450, protein binding, nicotinic acetylcholine receptors, biomarkers, neuroimaging
- MeSH terms
- Rivastigmine, Donepezil, Aging, Alzheimer Disease, Biological Availability, Carbamates, Cholinesterase Inhibitors, Drug Interactions, Half-Life, Humans, Indans, Intestinal Absorption, Liver, Piperidines, Protein Binding, Tacrine, Tissue Distribution, Phenylcarbamates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
